Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
Zheng JQ, Hou YC, Zheng CM, Lu CL, Liu WC, Wu CC, Huang MT, Lin YF, Lu KC
Nutrients · 20 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Taipei Medical University
- Universidad u hospital
- Shuang-Ho hospital, Taipei Medical University
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2016-11-05 · Nutrients · vol. 8 · número 11 · pág. 708
- Editorial
- Multidisciplinary Digital Publishing Institute
- Citado
- 25 citas · más que el 87% de estudios similares · 2.1× el promedio de su campo
- Referencias
- 52 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Parathyroid Disorders and Treatments · Vitamin D Research Studies · Dialysis and Renal Disease Management
- Palabras clave
- Paricalcitol, Parathyroid hormone, Secondary hyperparathyroidism, Cholecalciferol, Medicine, Vitamin D and neurology, Endocrinology, Internal medicine, Hyperparathyroidism, Hemodialysis, Urology, Calcium
- MeSH
- humans, kidney failure, chronic, hyperparathyroidism, secondary, cholecalciferol, calcifediol, ergocalciferols, parathyroid hormone, vitamin d, antimicrobial cationic peptides, placebos, treatment outcome, drug therapy, combination, renal dialysis, drug interactions, aged, middle aged, female, male, cathelicidins
9 autores
- Jing-Quan Zheng🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Yi‐Chou Hou🇹🇼Fu Jen Catholic University; Cardinal Tien Hospital
- Cai‐Mei Zheng🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Chien‐Lin Lu🇹🇼Taipei Medical University
- Wen-Chih Liu🇹🇼Fu Jen Catholic University; Cardinal Tien Hospital; Taipei Medical University
- Chia‐Chao Wu🇹🇼Tri-Service General Hospital; National Defense Medical Center
- Ming‐Te Huang🇹🇼Taipei Medical University-Shuang Ho Hospital
- Yuh‐Feng Lin🇹🇼Taipei Medical University-Shuang Ho Hospital; Taipei Medical University
- Kuo‐Cheng Lu🇹🇼 · autor de correspondenciaFu Jen Catholic University; Tri-Service General Hospital; Cardinal Tien Hospital; Taipei Medical University; National Defense Medical Center
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Active Vitamin D analogues are used clinically for prevention and treatment of secondary hyperparathyroidism (SHPT) in hemodialysis (HD) patients. Nutritional vitamin D supplementation is used for additional local parathyroid (PTH) suppression, with lower incidence of hypercalcemia and hyperphosphatemia. This study evaluates the possible beneficial effects of combined vitamin D treatment (paricalcitol and cholecalciferol).
Methods
Sixty HD patients with serum parathyroid hormone (iPTH) >300 pg/mL were enrolled. All patients administered 2 mcg/day of paricalcitol and were randomly allocated into control group (placebo) or study group (cholecalciferol) for 16 weeks. Serum 25(OH)D₃, iPTH and human cathelicidin (hCAP-18) were measured at baseline and during follow-up.
Results
iPTH levels decreased in the study group appropriately and were more significantly decreased at 16 weeks. Study group had significantly increased 25(OH)D₃ levels. In addition, the study group had significantly increased serum hCAP-18 levels compared with control group. Correlation analysis showed a significant correlation between the percentage increase in serum hCAP-18 and 25(OH)D₃ levels.
Conclusions
Cholecalciferol, in combination with paricalcitol, additively lowers the iPTH levels in a significant number of patients after 16 weeks of supplementation. A dose of 5000 IU/week of cholecalciferol could maintain serum 25(OH)D₃ levels above 30 ng/dL as early as 8 weeks after beginning supplementation. Doubling of serum cathelicidin levels were noted after 16 weeks of cholecalciferol supplementation in 40% of study patients.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.